New preclinical data will be presented at the American Association Of Cancer Research (AACR) Annual Meeting 2016 taking place from 16 to 20 April 2016, in New Orleans, Louisiana, USA.
These data supports the rationale of four of Innate’s clinical and preclinical programs:
- One poster will present preclinical data supporting the rationale for combining an NKG2A checkpoint inhibitor with a PD-1 or a PD-L1 checkpoint inhibitor in mouse models;
- One poster will present new data reinforcing the rationale for IPH4301, a first-in-class anti-MICA/B humanized antibody;
- Three posters will present preclinical data on new discovery programs targeting CD73 and CD39, immune checkpoints regulating the adenosine pathway, including one poster reporting data generated by OREGA Biotech, Innate’s collaborator on the CD39 project.
For more information, see press release
Beyond posters presentations, Innate Pharma’s team will be present with a booth (#2604) to receive its peers and the financial community at AACR.
Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will hold a conference call to the attention of analysts and portfolio managers to discuss the data published and Company’s innovative pipeline.
Time and dial in: Tuesday, April 19th 10:30am Eastern Time
USA: 888 504 7963
International: +1 719 325 2452
Access code: 1890466
---------
Ernest N. Morial Convention Center
New Orleans, Louisiana, USA